Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCorRx Inc.BICX · Entity 8179 | Director | September 29, 2023 | October 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCorRx Inc.
Report date September 29, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 114,065 |
Reported balance
After 2023-09-29 transaction · row 1
1 source rowRow 1 · 2023-09-29 · Grant · Acquired 2,858 · Balance 114,065 F1: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2023 Filed Oct 3, 2023 23:38 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007335 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,065 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:05 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005021 · form4.xml · nonDerivative · entry 2 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,207 F2 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. Read SEC document |
| March 31, 2023 Filed Jul 5, 2023 21:05 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005021 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,316 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 12:09 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 3 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,492 F3 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| September 30, 2022 Filed Jan 6, 2023 12:09 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 2 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,173 F2 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| June 30, 2022 Filed Jan 6, 2023 12:09 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,723 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:30 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002038 · form4.xml · nonDerivative · entry 2 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,631 F2 · kind: These shares were issued to Mr. Emry pursuant to the Director Agreement referenced in footnote 1. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55. Read SEC document |
| December 31, 2021 Filed Apr 4, 2022 21:30 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002038 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,223 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38. Read SEC document |
| September 30, 2021 Filed Oct 25, 2021 20:07 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-007561 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,082 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62. Read SEC document |
| June 30, 2021 Filed Jul 7, 2021 00:24 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-004471 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,701 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13. Read SEC document |
| March 31, 2021 Filed Apr 7, 2021 10:07 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-002084 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,491 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16. Read SEC document |
| September 30, 2020 Filed Oct 13, 2020 22:35 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-20-005861 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,275 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.